anonymous
Guest
anonymous
Guest
You're the pump expert What was the flaw, The Oxygen sensor ?
HR
HR
HR, I am asking you. YOU wrote that there was a design flaw in Symbiq, not me.You're the pump expert What was the flaw, The Oxygen sensor ?
HR
That is a most unreliable way of assassinating someone. How would the hit-man know when and what pump will be assigned to his target? You have been watching too many MI movies.You know more about the pump end than I do. Also don't downplay the cyber threat Sometimes key political and military decision makers are hospitalized and persons of interest wouldn't hesitate to employ an easy method to their advantage. A VA hospital is JUST as prone as a private hospital.
HR
One of the flaws on all of the pumps mentioned was the cyber issue
HR
That is a most unreliable way of assassinating someone. How would the hit-man know when and what pump will be assigned to his target? You have been watching too many MI movies.
No demo though, even after 2 years of these claims.
I can understand why Pfizer bought this line of business. They had no choice. They had to take the pumps to get the pharmaceuticals. But then, why would another company want to buy the pumps? Just because Pfizer wants to sell the pumps doesn't mean it will happen.MM has been on borrowed time for years. They are used to the uncertainty and knew for SURE their fate was sealed when big blue snatched Hospira. ....Just like ACCS and Precedex patent expiration ....... HR
Thanks for the explanation, HR. I always knew there was something funny going on with the infusion pumps. If that was what they were after, they did a pretty good job. They must have forced out the people who were trying to fix things to make money and promoted the guys who screwed things up to lose money. Managerial geniuses worked here.Some company's like to show a loss, then write the loss off. . . .
HR
Pfizer dumping the whole device end. Bye Bye MM
HR
Fierce Pharma
When Pfizer ($PFE) snatched up Hospira last year for $15 billion, the pharma giant said that it didn't have any plans to abandon Hospira's device business once the deal closes. But now Pfizer is having a change of heart, weighing an option to sell Hospira's pump and devices unit as Hospira struggles with its beleaguered business. The sale is still in early stages and Pfizer may choose not to hand off Hospira's devices and pump unit at this time, people familiar with the matter toldBloomberg. But if Hospira's pump business does go on the chopping block, it could bring in up to $2 billion for Pfizer, sources said. Pfizer is keeping quiet about its plans, with a representative from the company declining to comment to the news outlet.
Well, it has been over a month. Is anyone buying the pump business for $2billion?